NDA 208901 · Mayne Pharma
Tolsura
Itraconazole · Oral · Azole Antifungal
Last checked: Nov 20, 2026Latest source record: Oct 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Dec 11, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
507
27 Phase 3, 40 recruiting
FAERS reports
9,411
8,437 serious, 1,977 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CONGESTIVE HEART FAILURE and DRUG INTERACTIONS WARNING: CONGESTIVE HEART FAILURE and DRUG INTERACTIONS See full prescribing information for complete boxed warning. Congestive Heart Failure TOLSURA can cause or exacerbate congestive heart failure (CHF). When itraconazole was administered intravenously to healthy human volunteers and dogs, negative inotropic effects were seen. If signs or symptoms of congestive heart failure occur or worsen during administration of TOLSURA, reassess the benefit-risk of continuing treatment. ( 5.1 , 6 ). Drug Interactions Co-administration of certain drugs that are metabolized by human CYP3A4 enzymes are contraindicated with TOLSURA because plasma concentrations of such drugs are increased. ( 4.1 , 5.5 , 7.1 ) Co-administration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic...
What it is approved for
From the label in effect Apr 23, 2025.
TOLSURA is indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised adult patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-fungal therapy should be adjusted accordingly TOLSURA is an azole antifungal indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised adult patients ( 1 ): Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Limitations of Use: TOLSURA is not indicated for the treatment of onychomycosis ( 1 ) TOLSURA is NOT interchangeable or substitutable with other itraconazole products ( 1 ) Limitations of Use: TOLSURA is not indicated for the treatment of onychomycosis. TOLSURA is NOT interchangeable or substitutable with other itraconazole products due to the differences in the dosing between TOLSURA and other itraconazole products. Therefore, follow the specific dosage recommendations for TOLSURA [see Dosage and Administration (2) ].
Mechanism: Itraconazole is an azole antifungal drug [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- TOLSURA · ITRACONAZOLE 65MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Itraconazole" as an intervention, any sponsor and status, largest first.
BioNTech SEIndustry
NCT07070232 · 1,438 participants (planned) · Start Aug 12, 2025 · Primary completion Mar 2028
Drug: BNT326; Pumitamig and 2 more · For: Advanced Solid Tumor
Sites: Phoenix, Arizona; San Francisco, California; Hartford, Connecticut · 79 sites in all
- Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.Pivotal-lookingCompleted
Stiefel, a GSK CompanyIndustry
NCT00356915 · 1,381 participants · Start Jul 2006 · Primary completion Oct 2008
Drug: Itraconazole 100mg capsules; Itraconazole 200mg tablets and 1 more · For: Onychomycosis
Sites: Birmingham, Alabama; Tuscon, Arizona; Hot Springs, Arkansas · 68 sites in all
- Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and RehabilitationPivotal-lookingTerminated
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00675714 · 1,126 participants · Start Jan 2004 · Primary completion Sep 2018
Drug: Humatrope; Ketoconazole and 5 more · For: Burns
Sites: Galveston, Texas
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Recruiting
GenmabIndustry
NCT05579366 · 952 participants (planned) · Start Dec 7, 2022 · Primary completion Dec 2028
Drug: Rina-S; Carboplatin and 4 more · For: High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer; Primary Peritoneal Carcinoma and 13 more
Sites: Phoenix, Arizona; Tucson, Arizona; Los Angeles, California · 67 sites in all
DualityBio Inc.Industry
NCT05914116 · 862 participants (planned) · Start Aug 17, 2023 · Primary completion Dec 2027
Drug: DB-1311; Lopinavir and Ritonavir Tablets and 3 more · For: Advanced Solid Tumors
Sites: Tucson, Arizona; Los Angeles, California; Santa Monica, California · 107 sites in all
Nuvalent Inc.Industry
NCT05384626 · 840 participants (planned) · Start Jun 9, 2022 · Primary completion Dec 2027
Drug: Neladalkib (NVL-655); Midazolam and 2 more · For: Locally Advanced Solid Tumor; Metastatic Solid Tumor
Sites: Orange, California; Sacramento, California; Stanford, California · 74 sites in all
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsPivotal-lookingRecruiting
DualityBio Inc.Industry
NCT05150691 · 796 participants (planned) · Start Jan 31, 2022 · Primary completion Aug 2027
Drug: DB-1303/BNT323; Pertuzumab Injection and 2 more · For: HER2-positive Advanced Solid Tumor
Sites: Cerritos, California; Los Angeles, California; San Diego, California · 102 sites in all
- Anticoagulation in ICH Survivors for Stroke Prevention and RecoveryPivotal-lookingRecruiting
Yale UniversityAcademic, hospital or other
NCT03907046 · 700 participants (planned) · Start Jan 28, 2020 · Primary completion Apr 2027
Drug: Apixaban; Aspirin · For: Intracerebral Hemorrhage; Atrial Fibrillation
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 187 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,040
- drug interaction1,022
- off label use518
- pyrexia494
- pneumonia412
- febrile neutropenia341
- nausea334
- dyspnoea333
- condition aggravated320
- diarrhoea304
- neutropenia276
- anaemia251
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 146 |
| 2005 | 96 |
| 2006 | 146 |
| 2007 | 189 |
| 2008 | 208 |
| 2009 | 288 |
| 2010 | 250 |
| 2011 | 555 |
| 2012 | 464 |
| 2013 | 312 |
| 2014 | 286 |
| 2015 | 446 |
| 2016 | 341 |
| 2017 | 431 |
| 2018 | 589 |
| 2019 | 661 |
| 2020 | 712 |
| 2021 | 659 |
| 2022 | 538 |
| 2023 | 569 |
| 2024 | 524 |
| 2025 | 527 |
| 2026 | 473 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tolsura (Itraconazole)
2024 spending
$559K
Beneficiaries
43
195 claims
Per beneficiary
$13,007
$37.49 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $502,137 |
| 2021 | $902,242 |
| 2022 | $1,294,835 |
| 2023 | $769,425 |
| 2024 | $559,317 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA, Maertens J, Winston DJ, et al. · N Engl J Med 2007 · Comparative Study, Multicenter Study
- Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial.
Sehgal IS, Agarwal R, Dhooria S, et al. · Lancet Infect Dis 2026 · Randomized Controlled Trial, Comparative Study
- Coccidioidomycosis: clinical update.
Ampel NM, Wieden MA, Galgiani JN · Rev Infect Dis 1989 · Clinical Trial, Randomized Controlled Trial
- CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma.
Godet C, Brun AL, Couturaud F, et al. · Chest 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Itraconazole increases serum digoxin concentration.
Partanen J, Jalava KM, Neuvonen PJ · Pharmacol Toxicol 1996 · Clinical Trial, Randomized Controlled Trial
- Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.
Marks DI, Pagliuca A, Kibbler CC, et al. · Br J Haematol 2011 · Multicenter Study, Randomized Controlled Trial
Sponsor: Mayne Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.